Vectura receives support from Skyepharma shareholder
17th Mar 2016 11:52
(ShareCast News) - Vectura - which focuses on the development of pharmaceutical therapies for airways diseases - has received a letter of intent from a Skyepharma shareholder supporting the companies' proposed merger. Vectura said River and Mercantile Asset Management, which owns just under 4.8m Sky
Read moreSkyepharma and Vectura agree merger; Skyepharma swings to profit
16th Mar 2016 08:55
(ShareCast News) - Vectura and Skyepharma have reached an agreement on the terms of a recommended merger. Under the terms of the deal, Skyepharma shareholders will get 2.7977 new Vectura shares for each Skyepharma share. Based on Vectura's closing price of 146.60p on Tuesday, this values Skyepharma
Read moreSkyepharma 2015 revenue to be ahead of expectations
11th Jan 2016 08:19
(ShareCast News) - Skyepharma said on Monday that its full year revenues for 2015 are likely to be ahead of previous expectations thanks to a milestone payment. The oral and inhalation drug company said its license partner, Mundipharma, has agreed that the first sales milestone of €10m (£7.4m) for i
Read moreSkyepharma skips on Pacira's Exparel agreement with FDA
15th Dec 2015 10:39
(ShareCast News) - Skyepharma has been boosted by news that the US drug regulator has amicably resolved a dispute over Pacira Pharmaceuticals' Exparel drug, from which it receives a percentage of sales. Pacira, which pays Skyepharma 3% of net sales and is expected to also pay a sales milestones of $
Read moreSkyepharma shares gain on first half swing to profit
26th Aug 2015 11:45
(ShareCast News) - Shares in drug delivery company Skyepharma rose after the company swung to profit in the first half of the year. Skyepharma, which specialises in oral and inhalation products, said its pre-tax profit was £9.1m, compared with a £17.7m loss in the same period last year. Shares in S
Read moreSector movers: GSK leads defensive pharma stocks higher
4th Feb 2015 14:35
A massive cash return by Glaxosmithkline gave the wider sector a lift on Wednesday, with defensive healthcare and pharmaceutical stocks also benefiting from a reduction in risk appetite as UK markets pulled back from a five-month high. Sales, profits and earnings slumped during the fourth quarter of
Read moreSkyepharma climbs after launching Flutiform in Spain and Italy
1st Dec 2014 12:56
Skyepharma shares moved higher on Monday after the drug-maker announced that its Flutiform product has been launched in Spain and Italy. The group also announced its 120-puff version of Flutiform has been launched in Japan by its licensing partner, Kyorin Pharmaceuticals. The drug, which is used fo
Read moreTuesday broker round-up UPDATE
23rd Sep 2014 09:36
AVEVA: JP Morgan reduces target price from 2450p to 1825p, while leaving its overweight rating unchanged. African Minerals: Credit Suisse reduces target price from 120p to 25p, while leaving its neutral rating unchanged. Aviva: Goldman Sachs ups target price from 490p to 515p and reiterates a neutr
Read moreSkyepharma profits rise on Flutiform growth but rivals hit royalties
21st Aug 2014 08:24
Drug developer Skyepharma reported continued growth of its asthma inhaler Flutiform, but said royalties on some products were falling due to more competition. Skyepharma doubled sales of Flutiform compared with the second half of 2013 and launched the product in eight more countries including Franc
Read moreSector movers: Weak results, outlook from Glaxo sink pharma stocks
23rd Jul 2014 14:17
A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a
Read moreTuesday tips round-up: Quindell, SkyePharma
1st Apr 2014 07:03
Track records are important; hence, investors may want to carefully consider the investment thesis behind Quindell. The firm specialises in handling motor and household claims for insurers and now works in some way, shape or form, with the majority of the top ten insurers. Judged solely on its numbe
Read moreSkyepharma forecasts better-than-expected FY profits
31st Jan 2014 08:54
Oral and inhalation drug group Skyepharma forecast annual profits ahead of market hopes, sending its shares soaring. Skyepharma said it expected to report full year 2013 revenue and operating profit "materially ahead of market expectations". The group's Geomatrix and Geoclock technologies enable t
Read moreSector movers: AstraZeneca, Shire lift pharma stocks on upbeat guidance
14th Jan 2014 15:22
Decent gains from AstraZeneca and Shire gave the pharmaceuticals sector a boost on Tuesday as both firms gave confident outlooks. At the JP Morgan Healthcare Conference in San Francisco, AstraZeneca Chief Executive Pascal Soriot said he expects the company to return to growth sooner than analysts c
Read moreSkyepharma launches asthma drug Flutiform in Japan
19th Nov 2013 07:50
Drug developer Skyepharma has launched its Flutiform bronchial asthma treatment in Japan. Skyepharma's licensing partner Kyorin Pharmaceutical is marketing Flutiform and received a milestone of several million US dollars from Kyorin following regulatory approval in September 2013. Skyepharma is ent
Read moreSkyepharma warns flutiform(R) revenues to drop in second half
10th Oct 2013 10:04
Shares in Skyepharma, a drug delivery company, lost around five per cent of their value after the group admitted revenues from the supply of its flutiform(R) product are expected to be lower in the second half of the year. flutiform(R), which is used in the treatment of Chronic Obstructive Pulmona
Read more